Drug intelligence / Profile preview

JMEY-AX52

Development stage: Preclinical
Lead developer: Jianmin Pharmaceutical Group

Overview

JMEY-AX52 is a pediatric drug candidate being developed by Jianmin Pharmaceutical Group. It is currently in the CMC (Chemistry, Manufacturing, and Controls) and preclinical stages of development. The drug is specifically intended for use as an expectorant to facilitate the clearance of mucus from the respiratory tract. As part of Jianmin's dedicated pediatric pipeline, identified by the 'JMEY' prefix, it is being developed through the Jianmin Pediatric Research Institute. Detailed information regarding its specific molecular target, chemical structure, or modality has not been publicly disclosed.

Beyond the preview

Go deeper on JMEY-AX52.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-AX52.

Explore the full profile